1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. OMEGA THERAPEUTICS INC

Omega Therapeutics Inc XNAS: OMGAQ

Omega Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Download real time

0.04 0.02 (100.00%)

New 52W Low in past week

577.2K XNAS Volume

XNAS 27 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for Omega Therapeutics Inc is on 28 Mar 2025 for the purpose of Omega Therapeutics Inc Fourth Quarter Earnings Results for 2024 See details

Omega Therapeutics Inc Key Metrics

Select

Market Capitalization

Low in industry
2.2

Price to Book

Low in industry
0.2

Institutional holding current Qtr %

Below industry Median
87.4

Revenue Growth Qtr YoY %

High in industry
214.3

Operating Revenue growth TTM %

High in industry
184.9

Net Profit Qtr Growth YoY %

Below industry Median
26.1

Net Profit TTM Growth %

Below industry Median
32.3

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-628.6

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-916

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-99.1

ROE Annual %

Negative ROE Annual %
-118.8

RoA Annual %

Negative RoA Annual %
-55.6
All financials are in USD Million and price data in USD
VIEW MORE

6

S

15

W

0

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Omega Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '26050100Actual RevenueAvg. Estimate
Hit

Omega Therapeutics Inc's Revenue was higher than average estimate 2 times in past 2 years

EPS forecast

Current EPS
-1.8
Avg. Estimate
-1.2
Low Estimate
-1.2
High Estimate
-1.1
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 35.0% in FY24

Consensus Recommendation

7 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Hold2Buy4Strong Buy

The consensus recommendation from 7 analysts for Omega Therapeutics Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Omega Therapeutics Inc Stock Analysis

Omega Therapeutics Inc stock analysis with key metrics, changes, and trends.

Omega Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$3.09 M8.94%positive

Annual Revenue rose 8.94%, in the last year to $3.09 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$97.43 M9.82%positive

Annual Net Profit rose 9.82% in the last year to $97.43 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

Price to Earning Ratio-0.03-negative

Price to Earning Ratio is -0.03, which is negative.

Stock Price$0.04-98.82%negative

Stock Price fell 98.82% and underperformed its sector by 105.45% in the past year.

Quarterly Revenue$2.61 M214.32%positive

Quarterly Revenue rose 214.32% YoY to $2.61 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$16.44 M26.09%positive

Quarterly Net profit rose 26.09% YoY to $16.44 M. Its sector's average net profit growth YoY for the quarter was -47.41%.

Debt to Equity Ratio2.21-negative

Debt to Equity Ratio of 2.21 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE)-118.82 %-118.82%negative

Return on Equity(ROE) for the last financial year was -118.82%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding12.40 %-2.33%negative

Mutual Fund Holding decreased by 2.33% in the last quarter to 12.4.

Institutional Holding87.38 %-1.77%negative

Institutional Holding decreased by 1.77% in the last quarter to 87.38.

VIEW LESS


Loading data..

Omega Therapeutics Inc - Company Profile

What does Omega Therapeutics Inc do?

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.

Omega Therapeutics Inc Management structure

All Gross Remunerations are in USD
Ms. Barbara Y. Chan
Principal Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Joshua Reed
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Yan Moore, M.D.
Chief Medical Officer
-
2024
Gross Remuneration
Year
Dr. Kaan Certel, PhD
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Mahesh Karande
President, Chief Executive Officer and Director
-
2024
Gross Remuneration
Year

Omega Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Mr. Christian Stanton Schade
Chairman of the Board
-
2025
Gross Remuneration
Year
Mr. Ravi Mehrotra, PhD
Director
-
2025
Gross Remuneration
Year
Mr. Jeffrey T. Varsalone
Director
-
2025
Gross Remuneration
Year

Omega Therapeutics Inc FAQ

How is Omega Therapeutics Inc today?
Omega Therapeutics Inc today is trading in the green, and is up by 100.00% at 0.04.
Omega Therapeutics Inc is currently trading up 100.00% on an intraday basis. In the past week the stock rose 300.00%. stock has been down -95.12% in the past quarter and fell -98.82% in the past year. You can view this in the overview section.